Search
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018. … [L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Narsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigationaland pediatric patients aged 2 years and older. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawn[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981. … [L1138] These complexes are formed by the binding of 99mTc to metal atoms of an organic molecule.
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalThe first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.
Sulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalSulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Voretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigational[A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … When used in genetic therapy, this virus is modified for the elimination of its negligible integrative capacity by the removal of *rep* and *cap* and the insertion of the desired gene with its promoter
Guanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.
Peanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawnThe kernels are consumed roasted but a large percentage is used for the production of vegetable oil.
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]